PT  - JOURNAL ARTICLE
AU  - Roni Rasnic
AU  - Nathan Linial
AU  - Michal Linial
TI  - Expanding cancer predisposition genes with ultra-rare cancer-exclusive human variations
AID  - 10.1101/2020.01.09.19015867
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.01.09.19015867
4099  - http://medrxiv.org/content/early/2020/01/13/2020.01.09.19015867.short
4100  - http://medrxiv.org/content/early/2020/01/13/2020.01.09.19015867.full
AB  - It is estimated that up to 10% of cancer incidents are attributed to inherited genetic alterations. Despite extensive research, there are still gaps in our understanding of genetic predisposition to cancer. It was theorized that ultra-rare variants partially account for the missing heritable component. We harness the UK BioBank dataset of ∼500,000 individuals, 14% of which were diagnosed with cancer, to detect ultra-rare, possibly high-penetrance cancer predisposition variants. We report on 115 cancer-exclusive ultra-rare variations (CUVs) and nominate 26 variants with additional independent evidence as cancer predisposition variants. We conclude that population cohorts are valuable source for expanding the collection of novel cancer predisposition genes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for the presented work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMost of the data that support the findings of this study are available from the UKBB. However, restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are available from the authors upon a justified request and with permission of the UKBB. Data extracted from gnomAD is available from the authors upon request.